Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables RefundsShares OutstandingShort-Term Debt repayments
Ratios

BioNexus Gene Lab (BGLC) Receivables Refunds (2019 - 2025)

Historic Receivables Refunds for BioNexus Gene Lab (BGLC) over the last 7 years, with Q3 2025 value amounting to $103640.0.

  • BioNexus Gene Lab's Receivables Refunds rose 36828.12% to $103640.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $103640.0, marking a year-over-year increase of 36828.12%. This contributed to the annual value of $84167.0 for FY2024, which is 4615.37% up from last year.
  • As of Q3 2025, BioNexus Gene Lab's Receivables Refunds stood at $103640.0, which was up 36828.12% from $101471.0 recorded in Q2 2025.
  • BioNexus Gene Lab's Receivables Refunds' 5-year high stood at $103640.0 during Q3 2025, with a 5-year trough of $1767.0 in Q1 2022.
  • Moreover, its 5-year median value for Receivables Refunds was $31551.0 (2022), whereas its average is $41287.3.
  • Examining YoY changes over the last 5 years, BioNexus Gene Lab's Receivables Refunds showed a top increase of 164144.04% in 2023 and a maximum decrease of 9272.4% in 2023.
  • Quarter analysis of 5 years shows BioNexus Gene Lab's Receivables Refunds stood at $2727.0 in 2021, then surged by 1056.99% to $31551.0 in 2022, then soared by 82.52% to $57588.0 in 2023, then skyrocketed by 46.15% to $84167.0 in 2024, then grew by 23.14% to $103640.0 in 2025.
  • Its Receivables Refunds stands at $103640.0 for Q3 2025, versus $101471.0 for Q2 2025 and $89937.0 for Q1 2025.